Radiation therapy and androgen deprivation in the management of high risk prostate cancer
Int. braz. j. urol
;
37(2): 161-179, Mar.-Apr. 2011. graf, tab
Article
in English
| LILACS
| ID: lil-588990
ABSTRACT
The combined use of radiation therapy (RT) and androgen deprivation for patients with localized high-risk prostate cancer is commonly accepted as the standard treatment among uro-oncologists. Preclinical studies have provided rationale for the use of this combination. Additionally, results of phase 3 studies using conventional doses of RT have supported the combined approach. Other phase 3 studies have also shown a benefit for using higher doses of RT; however, the role of androgen deprivation in this context is not clear. The optimal duration of the androgen deprivation, in both the neoadjuvant and adjuvant setting, is still under investigation. This article critically reviews the data on the use of RT combined with androgen deprivation for the treatment of high-risk prostate cancer with emphasis on the results of phase 3 trials.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Prostatic Neoplasms
/
Antineoplastic Agents, Hormonal
/
Androgen Antagonists
Type of study:
Etiology study
/
Risk factors
/
Systematic reviews
Limits:
Humans
/
Male
Language:
English
Journal:
Int. braz. j. urol
Journal subject:
Urology
Year:
2011
Type:
Article
Affiliation country:
Canada
Similar
MEDLINE
...
LILACS
LIS